Side Effects and Resource Navigation Program for Cancer Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study evaluates a dedicated immunotherapy CARE Program to support patients starting PD-1 or PD-L1 inhibitors, aiming to improve treatment management and quality of life. Participants are adults in the New York metro region with specific cancers and at least one essential need, who begin immunotherapy within a defined timeframe. Outcomes include self-reported quality of life and other participant-reported experiences collected through questionnaires. The program is delivered within Memorial Sloan Kettering locations in New Jersey and surrounding areas. The trial does not have a listed phase and uses an interventional design.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Documentation of Disease

  o Patient must have pathologically confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR)
* Prior Treatment

  o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR)
* Age ≥ 18 (per EMR)
* Not Pregnant and Not Nursing (per self-report)
* At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report)
* Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance orand demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit) (per EMR or self-report)
* Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report)
* Can speak English or Spanish (per self-report)
* Has no serious life-threatening allergies to tape or adhesives (per EMR or self-report)
* Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team)
* Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)

Where it's running

• Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (All Protocol Activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (All Protocol Activities)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (All Protocol Activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Francesca Gany, MD, MS — Memorial Sloan Kettering Cancer Center
• Study coordinator: Francesca Gany, MD, MS
• Email: ganyf@mskcc.org
• Phone: 646-888-8054

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

• Timing smartphone messages to boost activity for older cancer survivors with chronic pain

  This study tests whether sending short smartphone messages at certain times can increase physical activity in older cancer survivors with chronic pain.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07227077

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Precision oncology navigation with expert genomic review to guide therapy and survival

  This tests whether a centralized precision oncology navigator and expert review of NGS results increase the use of genome-informed therapies for people with stage IV breast, lung, colorectal, or bladder cancer.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06896162

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.